Investors back Avraham Pharmaceuticals' Alzheimer's disease study
This article was originally published in Scrip
Executive Summary
Israel-based Avraham Pharmaceuticals will receive $9 million from a team of investors to fund a Phase IIb clinical trial of Ladostigil, a novel treatment for Alzheimer's disease.